32 results about "Beta-glycerophosphate" patented technology

The invention provides an inducing method and inducing culture medium for differentiation of bone marrow mesenchymal stem cells into osteoblasts in vitro. The inducing culture medium is composed of 1*10<-8> mol / L of dexamethasone, 50 mu mol / L of ascorbic acid and 10 mmol / L of sodium beta-glycerophosphate; and solvent is a supernatant of a sclerite complete culture medium and comprises 10% of fetal calf serum, 100 U / mL of penicillin, 100 mg / L of streptomycin, a mixture of DMEM culture fluid and F12 culture fluid and multiple growth factors secreted by bone cells in the sclerite culture process. According to the invention, bone marrow mesenchymal stem cells of a mouse are purified by replacing the cell culture fluid through an adherent cell passage method, the obtained cells of the first generation are induced, and the supernatant of the sclerite complete culture medium cultured for 72-96 hours is used as the solvent of osteoblast differentiation inducer, thereby obviously improving the in vitro osteogenic differentiation efficiency of bone marrow mesenchymal stem cells.

The invention discloses injectable chitosan / keratin composite hydrogel capable of promoting myocardium repair and a preparation method of the hydrogel. The hydrogel consists of four solutions, namely chitosan, sodium beta-glycerophosphate, genipin and keratin according to a volume ratio of 10: (1-5): (1-3): (0.1-0.5). The preparation method comprises the following steps: 1) extracting keratin from human fairs by using peracetic acid and Tris alkaline; 2) adjusting the pH value of a water-soluble chitosan solution by using sodium beta-glycerophosphate so as to be close to a microenvironment in a human body; 3) introducing genipin as a crosslinking agent, and controlling the gelling time of a hydrogel solution by changing the use amount of the genipin so as to achieve the purpose that the mixed solution can be rapidly gelled in situ after being injected into an organism. Experiments prove that the composite hydrogel has favorable biocompatibility and has the capability of remarkably promoting the growth of myocardial cells; the hydrogel is wide in sources of materials and low in cost and has a broad application prospect in the field of tissue engineering repair.

The invention relates to a temperature-sensitive controlled-release pharmaceutical composition of taxane drugs. Specifically speaking, the invention relates to the pharmaceutical composition which comprises taxane drugs, chitosan, sodium beta-glycerophosphate, ethanol and water, and further relates to a preparation method for the pharmaceutical composition. The pharmaceutical composition can be used for preparation of anticancer drugs. In particular, the anticancer drugs are applied to treatment of malignant tumors or prevention of recurrence after operation through a stereotaxical injection approach and can be cooperatively used with radiotherapy and traditional Chinese medicine.

The invention provides MTX subcutaneous sustained-release injection CS / GP / MAX (Methotrexate-loaded Chitosan-based Thermosensitive Hydrogel). Every liter of aqueous solution of the CS / GP / MAX contains 16 to 22 grams of chitosan, 0.05 to 0.1 mole of acetic acid, 70 to 150 grams of beta-glycerophosphate, 0.1 to 0.12 mole of methotrexate, 0.1 to 0.12 mole of a solubilizer and 5 to 50 grams of an isoosmotic adjusting agent and pH modifier. The CS / GP / MAX has stable properties and controllable quality, and the external properties, tgel (the time of gelation), eta, pH value, content and preliminary stability of the CS / GP / MAX meet requirements on thermosensitive hydrogel; 70 percent of drugs of the CS / GP / MAX in a PBS (Phosphate Buffer Solution) are released within 5 days under the condition of 37 DEG C; compared with those of MTX injection, the Cmax (Maximum Plasma Drug Concentration) is reduced by 82 percent, the AUC0-t (area under the plasma concentration time curve from time 0 to t hours) is enlarged by 2.37 times, and the t0.02muM (the length of time the MTX concentration-time curve remained above 0.02 muM in one week) is prolonged by 12.93 times after the CS / GP / MAX is subcutaneously injected to the back of a rabbit; by the CS / GP / MAX, adverse effects can be reduced, and curative effects can be improved.

The invention discloses a ferrite / BCG / temperature-sensitive gel integrated material, which comprises 5%-15% of BCG, 5%-15% of ferric oxide, 70%-90% of chitosan / Sodium β-glycerophosphate xerogel. The preparation method of the integrated material is to prepare nano ferric oxide by co-precipitation method; dissolve chitosan in dilute hydrochloric acid, add quantitatively prepared ferric oxide and BCG, disperse evenly, and then add β-sodium glycerophosphate dropwise The solution is heated in a water bath to convert the mixed solution into a gel; the obtained gel is freeze-dried or vacuum-dried to obtain a chitosan xerogel; the xerogel is ground and sieved to obtain a corresponding integrated material. The integrated material prepared by the present invention has the function of targeting wall attachment and sustained release. The integrated material powder can be attached to the inner wall of the bladder under the action of an external magnetic field so as not to be excreted with urine, prolonging the time it stays in the bladder and strengthening the BCG. efficacy.

The invention relates to a doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel and a preparation method thereof. The doxorubicin hydrochloride loaded temperature-sensitive self-healing hydrogel comprises chitosan, sodium beta-glycerophosphate, and polyethylene glycol with two ends respectively carrying a benzaldehyde group. The preparation method comprises the following steps: forming an imide bond with a self-healing performance through using a reaction of an amino group in the structure of chitosan and the benzaldehyde groups at two ends of the polyethylene glycol, combining the imide bond with chitosan / sodium beta-glycerophosphate temperature-sensitive gel, and loading doxorubicin hydrochloride into the obtained material through physical clathration to prepare the novel temperature-sensitive self-healing hydrogel administration system. The administration system is a liquid at room temperature, and rapidly gelates at a human body temperature after being injected to a tumor position in order to form a medicine reservoir ; and compared with traditional in situ gels, the temperature-sensitive self-healing hydrogel has the advantages of strong mechanical strength, realization of rapid self restoration under the action of outside force or tissue damages to avoid burst release of a medicine, further delay of release of the medicine and prolongation of the detention time of the medicine in the tumor position, medicine effect enhancement and reduction of toxic and side effects.